Liquidia Technologies

Liquidia Technologies is developing engineered particle-based vaccines and therapeutics that have the potential to dramatically improve the quality of human life. Utilizing a novel technology known as the PRINT® platform, Liquidia is creating rationally-design carriers for improved delivery of small molecule and biological cargos.

By designing highly specific particles that deliver therapies to an intended target, Liquidia is uncovering ways to optimize the safety and efficacy of vaccines and therapeutics. Liquidia's PRINT platform makes it possible for the first time to design particles with independent and precise control of particle size, shape, chemistry, surface functionality, and flexibility.